Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials

Diabetes, Obesity & Metabolism
Robert R HenryHenry N Ginsberg

Abstract

This analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using pooled data from 10 phase 3 ODYSSEY trials. Data from 4983 randomized patients (1940 with MetS; 1642 with diabetes excluded) were assessed in subgroups by MetS status. Efficacy data were analysed in 4 pools per study design: 2 placebo-controlled pools (1 using alirocumab 150 mg every 2 weeks [Q2W], 1 using 75/150 mg Q2W) with background statin, and 2 ezetimibe-controlled pools (both alirocumab 75/150 mg Q2W), 1 with and 1 without background statin. Alirocumab 75/150 mg indicates possible dose increase from 75 to 150 mg at Week 12 based on Week 8 LDL-C. LDL-C percentage reduction from baseline at Week 24 with alirocumab was 63.9% (MetS) and 56.8% (non-MetS) in the pool of alirocumab 150 mg Q2W, and 42.2% to 52.2% (MetS) and 45.0% to 52.6% (non-MetS) in 3 pools using 75/150 mg Q2W. Levels of other lipid and lipoprotein parameters were also improved with alirocumab treatment, including apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein(a) and HDL-C. Overall, the percentage change at Week 24 in LDL-C and other lipids and ...Continue Reading

References

Apr 30, 2003·Diabetes·Charles M AlexanderUNKNOWN National Cholesterol Education Program (NCEP)
Jul 20, 2007·JAMA : the Journal of the American Medical Association·Børge G NordestgaardAnne Tybjaerg-Hansen
Sep 25, 2010·Journal of the American College of Cardiology·Salvatore MottilloMark J Eisenberg
Jun 23, 2011·JAMA : the Journal of the American Medical Association·David PreissKausik K Ray
Aug 17, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Christian Rask-Madsen, C Ronald Kahn
Feb 18, 2014·Journal of Clinical Lipidology·UNKNOWN Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members
Apr 9, 2014·Cardiology Research and Practice·Jaspinder Kaur
Mar 17, 2015·The New England Journal of Medicine·Jennifer G RobinsonUNKNOWN ODYSSEY LONG TERM Investigators
Apr 26, 2015·Journal of Clinical Lipidology·Terry A JacobsonW Virgil Brown
Jun 2, 2015·The Journal of Clinical Endocrinology and Metabolism·Harold BaysStephen Donahue
Oct 23, 2015·Current Atherosclerosis Reports·Tomáš StulcAntonio M Gotto
Dec 22, 2015·Journal of Clinical Lipidology·Patrick M MoriartyUNKNOWN ODYSSEY ALTERNATIVE Investigators
Feb 20, 2016·Journal of Clinical Lipidology·Harold E BaysTerry A Jacobson
Dec 14, 2016·The New England Journal of Medicine·Brian A FerenceMarc S Sabatine
Dec 18, 2016·Circulation·Gissette Reyes-SofferHenry N Ginsberg
Feb 9, 2017·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Niranjan BidargaddiJörg Strobel
Jul 29, 2017·World Journal of Diabetes·Theodosios D FilippatosMoses S Elisaf

❮ Previous
Next ❯

Citations

Dec 7, 2018·Diabetes, Obesity & Metabolism·Robert J ChiltonSon Pham
Jul 28, 2019·Current Atherosclerosis Reports·Julia Brandts, Dirk Müller-Wieland
Oct 11, 2020·Current Opinion in Cardiology·Amélie PaquinMarie-Eve Piché

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01709513
NCT01644175
NCT01644188
NCT01623115
NCT01709500
NCT01617655
NCT01507831
NCT01644474
NCT01730040
NCT01730053

Software Mentioned

ODYSSEY

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.